insights_auto
Why is XMP1 up 10.27%?
Dive Deeperchevron_right
XMP1:FRA
Cerenome, Inc.
€0.58
arrow_upward
+10.27%(+0.054) 1D
Nov 10, 10:00:00 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for XMP1...
Open
€0.44
High
€0.58
Low
€0.44
Mkt. cap
4.22M
Avg. vol.
9.00
Volume
1.48K
52-wk high
€6.27
52-wk low
€0.44
No. of employees
28
Open
€0.44
High
€0.58
Low
€0.44
Mkt. cap
4.22M
Avg. vol.
9.00
Volume
1.48K
52-wk high
€6.27
52-wk low
€0.44
No. of employees
28
News stories
From web sources and news partners
Investing.com
·
15 hours ago
Cerenome names Ron Andrews as chief business officer
StreetInsider
·
16 hours ago
Cerenome names board member Ron Andrews as chief business officer
The Manila Times
·
16 hours ago
Cerenome Appoints Director Ron Andrews as Chief Business Officer
Profile
Cerenome, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®. Wikipedia
About Cerenome, Inc.